Vir Biotechnology (VIR) News Today $9.57 -0.23 (-2.35%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$9.89 +0.32 (+3.34%) As of 02/21/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Vir Biotechnology director George Scangos sells $107,575 in stockFebruary 22 at 12:54 AM | investing.comGeorge A. Scangos Sells 10,964 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director George A. Scangos sold 10,964 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 20 at 8:34 PM | marketbeat.comVir Biotechnology (VIR) to Release Earnings on ThursdayVir Biotechnology (NASDAQ:VIR) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665614)February 20 at 2:31 AM | marketbeat.comVir Biotechnology to Participate in TD Cowen 45th Annual Health Care ConferenceFebruary 19 at 4:05 PM | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini Sells 1,562 SharesVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 1,562 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $9.15, for a total transaction of $14,292.30. Following the sale, the chief accounting officer now directly owns 28,189 shares in the company, valued at $257,929.35. This trade represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.February 15, 2025 | marketbeat.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Sells 1,562 Shares of StockFebruary 15, 2025 | insidertrades.comEmpowered Funds LLC Lowers Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Empowered Funds LLC cut its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 290,626 shares of the company's stock after selling 39,February 15, 2025 | marketbeat.comVir Biotechnology SVP sells shares for $14,291February 14, 2025 | msn.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives $34.83 Consensus Target Price from AnalystsFebruary 14, 2025 | americanbankingnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Irhythm Technologies (IRTC), Vir Biotechnology (VIR) and Biogen (BIIB)February 13, 2025 | markets.businessinsider.comState of Alaska Department of Revenue Increases Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)State of Alaska Department of Revenue increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 33.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,441 shares ofFebruary 13, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Down 4.8% - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Stock Price Down 4.8% - Here's What HappenedFebruary 10, 2025 | marketbeat.comabrdn plc Invests $2.67 Million in Vir Biotechnology, Inc. (NASDAQ:VIR)abrdn plc purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 363,161 shares of the company's stock, valued at approximately $2,666,000.February 10, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendatioFebruary 7, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for VIR FY2029 Earnings?Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Stock analysts at HC Wainwright reduced their FY2029 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Friday, January 31st. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $2February 3, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Sees Significant Increase in Short InterestVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 7,860,000 shares, a growth of 20.0% from the December 31st total of 6,550,000 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is currently 3.7 days. Currently, 9.0% of the company's shares are sold short.February 1, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)HC Wainwright reissued a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a research report on Friday.January 31, 2025 | marketbeat.comVir Biotechnology appoints new Chief Technical OfficerJanuary 31, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Shares Down 3.8% - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.8% - Should You Sell?January 24, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Up 6.3% - What's Next?Vir Biotechnology (NASDAQ:VIR) Trading Up 6.3% - Time to Buy?January 23, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 10.4% - What's Next?Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Should You Sell?January 15, 2025 | marketbeat.comVir Biotechnology Receives Buy Rating: Promising TCE Programs and Strategic Focus Boost Growth OutlookJanuary 15, 2025 | markets.businessinsider.comQ1 Earnings Forecast for VIR Issued By Leerink PartnrsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings ofJanuary 15, 2025 | marketbeat.comJPMorgan Chase & Co. Has $8.14 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)JPMorgan Chase & Co. cut its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 13.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,086,327 shares of the company's stock after selling 168,971 sharJanuary 15, 2025 | marketbeat.comResearch Analysts Offer Predictions for VIR Q2 EarningsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings peJanuary 14, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Here's WhyVir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Time to Sell?January 13, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have iJanuary 13, 2025 | marketbeat.comLeerink Partners Issues Positive Forecast for Vir Biotechnology (NASDAQ:VIR) Stock PriceLeerink Partners lifted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday.January 13, 2025 | marketbeat.comNordea Investment Management AB Has $1 Million Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Nordea Investment Management AB trimmed its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 67.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 136,487 shares of the company's sJanuary 13, 2025 | marketbeat.comVir Biotechnology: Buy Rating Supported by Promising TCE Programs and Strategic PartnershipsJanuary 11, 2025 | markets.businessinsider.comMorgan Stanley Doubles Vir Biotechnology Price Forecast - Here's WhyJanuary 10, 2025 | benzinga.comVir Biotechnology (NASDAQ:VIR) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday.January 10, 2025 | marketbeat.comVir Biotechnology upgraded to Overweight from Equal Weight at Morgan StanleyJanuary 10, 2025 | markets.businessinsider.comVir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%January 10, 2025 | finance.yahoo.comMorgan Stanley Upgrades Vir Biotechnology (VIR)January 10, 2025 | msn.comMorgan Stanley Sees 67% Upside Potential for Vir Biotechnology StockJanuary 9, 2025 | finance.yahoo.comVir Biotechnology: A Rocket Off Phase 1 DataJanuary 9, 2025 | seekingalpha.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $14.00 at JPMorgan Chase & Co.JPMorgan Chase & Co. increased their target price on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research report on Thursday.January 9, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Morgan StanleyMorgan Stanley upgraded shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $10.00 to $20.00 in a report on Thursday.January 9, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Time to Buy?Vir Biotechnology (NASDAQ:VIR) Reaches New 1-Year High - Time to Buy?January 9, 2025 | marketbeat.comVir Biotechnology’s Early Promise in Clinical Trials Warrants Hold Rating Amid UncertaintiesJanuary 9, 2025 | markets.businessinsider.comVir Biotechnology’s Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term UncertaintiesJanuary 9, 2025 | markets.businessinsider.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) Director Sells 10,960 Shares of StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki L. Sato sold 10,960 shares of the firm's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now directly owns 1,312,391 shares of the company's stock, valued at $16,431,135.32. This represents a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 8, 2025 | marketbeat.comVir Biotechnology stock soars on promising trial dataJanuary 8, 2025 | au.investing.comVir Biotechnology price target lowered to $14 from $15 at BofAJanuary 8, 2025 | finance.yahoo.comVir Biotech Shares Rise on Positive Data for Cancer TreatmentsJanuary 8, 2025 | marketwatch.comVir Biotechnology’s Promising TCE Oncology Assets Earn Buy Rating from Joseph StringerJanuary 8, 2025 | markets.businessinsider.comVir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in CancerJanuary 8, 2025 | msn.comVir Biotechnology Catapults 64% On Promising Results In Cancer TreatmentJanuary 8, 2025 | msn.comVir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's WhyJanuary 8, 2025 | benzinga.com Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.460.60▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼75▲VIR Articles Average Week Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VRNA News GRFS News TGTX News KRYS News SWTX News BHVN News RXRX News PTCT News OGN News RARE News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VIR Stock Alerts